10 January 2022 - At the beginning of the year, the Federal Joint Committee (G-BA) took stock of its assessment of new drugs in 2021.
In addition to a record number of assessments, the G-BA was able to award the highest seal of quality "significant additional benefit" five times.
The year 2021 was also diverse in terms of content and therapy: in addition to many new cancer drugs, the G-BA also evaluated the first antiviral drug against COVID-19, novel gene therapy drugs and high-priced active ingredients against spinal muscular atrophy.